A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (BUILD UC)

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (BUILD UC)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs F8 IL10 (Primary) ; Infliximab
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 26 Sep 2019 to 24 Mar 2020.
    • 25 Sep 2017 Planned primary completion date changed from 26 Sep 2019 to 24 Mar 2020.
    • 04 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top